Developer docs
API playgroundTry for free, no card

Search company profiles

T2 Biosystems

Full company profile

uuid0004jx1

Namestring
T2 Biosystems
Legal namestring
T2 Biosystems, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

T2 Biosystems, Inc. was a medical diagnostics company that developed the T2Dx rapid diagnostic platform for detecting sepsis-causing pathogens and antimicrobial resistance directly from patient blood samples, eliminating the need for traditional blood culture. The T2Dx system received de novo FDA authorization in 2014, establishing a first-mover regulatory position in culture-independent blood pathogen detection. The company targeted hospital laboratories and healthcare institutions as its core customer segment and generated revenue through sales of the T2Dx instrument and associated diagnostic consumable panels via an enterprise field-sales motion. Headquartered in Lexington, Massachusetts, and listed on NASDAQ under ticker TTOO, T2 Biosystems pursued international expansion and additional panel FDA submissions as growth vectors.

The company's business model centered on a razor-and-blade hardware/consumables structure, though specific pricing was not publicly disclosed. Enterprise contracts to hospital systems drove instrument placements, with consumable panels representing the recurring revenue layer. Strategic partners included CRG Servicing LLC as a major debt holder (subsequently converted $15M to equity in February 2024) and BARDA, which awarded a $3.7 million base grant in September 2022 with up to $62.0 million in additional option funding tied to clinical and regulatory milestones.

Despite a recognized regulatory moat and meaningful federal-program support, T2 Biosystems failed to reach commercial scale. Revenue contracted from approximately $22.3M in 2022 to $7.2M in 2023 against net losses of roughly $50M, indicating cost-of-revenue exceeded topline. Repeated dilutive financings — including an $8M private placement in May 2024 — could not stem the cash burn. Nasdaq suspended TTOO trading on February 12, 2025; all employees were terminated thereafter. An investment-bank-led sale process failed to find a buyer capable of satisfying secured indebtedness, and on February 3, 2026 the company announced an immediate wind-down and voluntary liquidation. The T2Biosystems.com domain is no longer resolvable, consistent with the company's dissolved operating state.

Short descriptiontext

T2 Biosystems was a medical diagnostics company that developed the T2Dx rapid pathogen detection platform, enabling hospital laboratories to identify bloodstream infections and antimicrobial resistance directly from blood samples without traditional blood culture. The company ceased operations in early 2026.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid diagnostics, sepsis detection, blood pathogen testing, clinical diagnostics, antimicrobial resistance testing
Industry1 code
PRIMARYHLAHAAAH
Blood Bank, Transfusion Medicine & Immunohematology
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Equipment and Supplies Manufacturing33911
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
In Vitro Diagnostics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Diagnostics Equipment and Consumables
TypeHardware Sales
Description

T2 Biosystems generated revenue through sales of its T2Dx diagnostic instrument system and associated diagnostic panels/consumables to healthcare institutions including hospitals and laboratories.

fortunebusinessinsights.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

T2 Biosystems developed and sold the T2Dx Instrument, a rapid diagnostic system that identifies sepsis-causing pathogens and antimicrobial resistance directly from whole blood samples without requiring traditional blood culture. The company offered the instrument together with associated diagnostic panels/consumables to hospital laboratories and healthcare institutions for time-critical bloodstream infection diagnosis.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

T2 Biosystems offered a single core product platform, the T2Dx Instrument, which was a rapid diagnostic system for detecting pathogens and antibiotic resistance markers directly from blood samples. The company's proprietary technology eliminated the need for traditional blood culture methods, enabling faster diagnosis of sepsis and other bloodstream infections.

Product and service1 record
1T2Dx Instrument
CategoryRapid Diagnostic Instrument
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global leader in in vitro diagnostics and clinical microbiology. Directly comparable to T2 Biosystems as both sell blood-pathogen identification and antimicrobial resistance testing solutions to hospital labs, with bioMérieux's BioFire and VITEK lines representing the dominant direct-from-blood molecular and culture-based alternatives to T2Dx.

TypeDirect peer
Description

Molecular diagnostics company (owned by Danaher) whose GeneXpert system provides rapid PCR-based pathogen detection including from blood samples. Closely comparable to T2Dx as a direct-from-specimen rapid molecular platform sold to hospital and reference laboratories.

TypeBroad incumbent
Description

Large incumbent in clinical microbiology, blood culture, and molecular diagnostics (BD MAX, BD Phoenix, BD BACTEC). Overlaps directly with T2's hospital-lab customer base and sepsis/bloodstream-infection diagnostic workflow, though BD's portfolio is far broader.

TypeDirect peer
Description

Commercial-stage company developing rapid identification and antimicrobial susceptibility testing directly from patient samples, including blood. Direct competitor in the rapid sepsis/AST diagnostics niche that T2Dx targeted.

TypeBroad incumbent
Description

Global diagnostics incumbent offering molecular, clinical chemistry, and microbiology solutions (incl. cobas and GenMark ePlex post-acquisition). Comparable to T2 as a hospital-focused IVD player with overlapping blood-pathogen molecular testing capabilities.

TypeBroad incumbent
Description

Diversified diagnostics and women's health company whose molecular diagnostics business (e.g., Panther system, BioFire acquisition history) competes in rapid pathogen detection. Comparable to T2 as a molecular-IVD peer serving hospital labs.

TypeBroad incumbent
Description

Global molecular diagnostics and sample-technology company with products in infectious disease testing and IVD reagent manufacturing. Overlaps with T2 in the broader molecular IVD and infectious-disease workflow serving clinical labs.

TypeEmerging player
Description

Specialized developer of molecular and immunodiagnostic assays for infectious disease and biothreat agents, with historical BARDA funding overlap with T2. Comparable as a niche, technology-focused molecular diagnostics peer in the biodefense and sepsis-adjacent space.

9Qvella
TypeEmerging player
Description

Early-stage diagnostics company developing rapid pathogen identification directly from blood without culture, conceptually mirroring T2Dx's core workflow. Comparable as an emerging competitor in the direct-from-blood rapid ID niche.

TypeDirect peer
Description

Molecular diagnostics company (acquired by Roche) whose ePlex system provides rapid syndromic and blood-pathogen testing for hospital labs. Direct comparator to T2Dx as a sample-to-answer molecular platform serving similar sepsis/bloodstream-infection use cases.

Market position
Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

T2 Biosystems

In Vitro Diagnosticst2biosystems.com

T2 Biosystems was a medical diagnostics company that developed the T2Dx rapid pathogen detection platform, enabling hospital laboratories to identify bloodstream infections and antimicrobial resistance directly from blood samples without traditional blood culture. The company ceased operations in early 2026.

What T2 Biosystems does

T2 Biosystems, Inc. was a medical diagnostics company that developed the T2Dx rapid diagnostic platform for detecting sepsis-causing pathogens and antimicrobial resistance directly from patient blood samples, eliminating the need for traditional blood culture. The T2Dx system received de novo FDA authorization in 2014, establishing a first-mover regulatory position in culture-independent blood pathogen detection. The company targeted hospital laboratories and healthcare institutions as its core customer segment and generated revenue through sales of the T2Dx instrument and associated diagnostic consumable panels via an enterprise field-sales motion. Headquartered in Lexington, Massachusetts, and listed on NASDAQ under ticker TTOO, T2 Biosystems pursued international expansion and additional panel FDA submissions as growth vectors.

The company's business model centered on a razor-and-blade hardware/consumables structure, though specific pricing was not publicly disclosed. Enterprise contracts to hospital systems drove instrument placements, with consumable panels representing the recurring revenue layer. Strategic partners included CRG Servicing LLC as a major debt holder (subsequently converted $15M to equity in February 2024) and BARDA, which awarded a $3.7 million base grant in September 2022 with up to $62.0 million in additional option funding tied to clinical and regulatory milestones.

Despite a recognized regulatory moat and meaningful federal-program support, T2 Biosystems failed to reach commercial scale. Revenue contracted from approximately $22.3M in 2022 to $7.2M in 2023 against net losses of roughly $50M, indicating cost-of-revenue exceeded topline. Repeated dilutive financings — including an $8M private placement in May 2024 — could not stem the cash burn. Nasdaq suspended TTOO trading on February 12, 2025; all employees were terminated thereafter. An investment-bank-led sale process failed to find a buyer capable of satisfying secured indebtedness, and on February 3, 2026 the company announced an immediate wind-down and voluntary liquidation. The T2Biosystems.com domain is no longer resolvable, consistent with the company's dissolved operating state.

T2 Biosystems firmographics

Firmographics
Name
T2 Biosystems
Legal name
T2 Biosystems, Inc.
Website
https://t2biosystems.com
Company type
Public
Founded year
2014
Operating status
Closed
Headcount range
51–100 employees
Short description
T2 Biosystems was a medical diagnostics company that developed the T2Dx rapid pathogen detection platform, enabling hospital laboratories to identify bloodstream infections and antimicrobial resistance directly from blood samples without traditional blood culture. The company ceased operations in early 2026.
Ownership category
akta.pro rank

T2 Biosystems industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (33911)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAH
Blood Bank, Transfusion Medicine & Immunohematology
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Rapid diagnostics
  • Sepsis detection
  • Blood pathogen testing
  • Clinical diagnostics
  • Antimicrobial resistance testing

Where T2 Biosystems is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

T2 Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Diagnostics Equipment and Consumables: T2 Biosystems generated revenue through sales of its T2Dx diagnostic instrument system and associated diagnostic panels/consumables to healthcare institutions including hospitals and laboratories.

Go-to-market motion1 record

Distribution channels1 record

T2 Biosystems product offering

Product offering

Core offering

T2 Biosystems developed and sold the T2Dx Instrument, a rapid diagnostic system that identifies sepsis-causing pathogens and antimicrobial resistance directly from whole blood samples without requiring traditional blood culture. The company offered the instrument together with associated diagnostic panels/consumables to hospital laboratories and healthcare institutions for time-critical bloodstream infection diagnosis.

Product overview

T2 Biosystems offered a single core product platform, the T2Dx Instrument, which was a rapid diagnostic system for detecting pathogens and antibiotic resistance markers directly from blood samples. The company's proprietary technology eliminated the need for traditional blood culture methods, enabling faster diagnosis of sepsis and other bloodstream infections.

Differentiator

Problem solved

Functional benefit

Products and services

  • T2Dx Instrument

Companies that use T2 Biosystems

Customer profile

Segments1 record

Ideal customer profiles1 record

T2 Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

T2 Biosystems partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights2 records

T2 Biosystems competitors and assessment

Company assessment

Direct peers

  • bioMérieux: Global leader in in vitro diagnostics and clinical microbiology. Directly comparable to T2 Biosystems as both sell blood-pathogen identification and antimicrobial resistance testing solutions to hospital labs, with bioMérieux's BioFire and VITEK lines representing the dominant direct-from-blood molecular and culture-based alternatives to T2Dx.
  • Cepheid (Danaher): Molecular diagnostics company (owned by Danaher) whose GeneXpert system provides rapid PCR-based pathogen detection including from blood samples. Closely comparable to T2Dx as a direct-from-specimen rapid molecular platform sold to hospital and reference laboratories.
  • Accelerate Diagnostics: Commercial-stage company developing rapid identification and antimicrobial susceptibility testing directly from patient samples, including blood. Direct competitor in the rapid sepsis/AST diagnostics niche that T2Dx targeted.
  • GenMark Diagnostics: Molecular diagnostics company (acquired by Roche) whose ePlex system provides rapid syndromic and blood-pathogen testing for hospital labs. Direct comparator to T2Dx as a sample-to-answer molecular platform serving similar sepsis/bloodstream-infection use cases.

Broad incumbents

  • Becton, Dickinson and Company (BD): Large incumbent in clinical microbiology, blood culture, and molecular diagnostics (BD MAX, BD Phoenix, BD BACTEC). Overlaps directly with T2's hospital-lab customer base and sepsis/bloodstream-infection diagnostic workflow, though BD's portfolio is far broader.
  • Roche Diagnostics: Global diagnostics incumbent offering molecular, clinical chemistry, and microbiology solutions (incl. cobas and GenMark ePlex post-acquisition). Comparable to T2 as a hospital-focused IVD player with overlapping blood-pathogen molecular testing capabilities.
  • Hologic: Diversified diagnostics and women's health company whose molecular diagnostics business (e.g., Panther system, BioFire acquisition history) competes in rapid pathogen detection. Comparable to T2 as a molecular-IVD peer serving hospital labs.
  • QIAGEN: Global molecular diagnostics and sample-technology company with products in infectious disease testing and IVD reagent manufacturing. Overlaps with T2 in the broader molecular IVD and infectious-disease workflow serving clinical labs.

Emerging players

  • Tetracore: Specialized developer of molecular and immunodiagnostic assays for infectious disease and biothreat agents, with historical BARDA funding overlap with T2. Comparable as a niche, technology-focused molecular diagnostics peer in the biodefense and sepsis-adjacent space.
  • Qvella: Early-stage diagnostics company developing rapid pathogen identification directly from blood without culture, conceptually mirroring T2Dx's core workflow. Comparable as an emerging competitor in the direct-from-blood rapid ID niche.

Market position

Weaknesses1 record

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

T2 Biosystems social profiles

Digital presence

T2 Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

T2 Biosystems leadership team

Management profile

Number of profiles

Profiles5 records

T2 Biosystems funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

T2 Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about T2 Biosystems

What does T2 Biosystems do?

T2 Biosystems developed and sold the T2Dx Instrument, a rapid diagnostic system that identifies sepsis-causing pathogens and antimicrobial resistance directly from whole blood samples without requiring traditional blood culture. The company offered the instrument together with associated diagnostic panels/consumables to hospital laboratories and healthcare institutions for time-critical bloodstream infection diagnosis.

Is T2 Biosystems a public or private company?

T2 Biosystems is a public company. It is classified as public and is currently closed.

When was T2 Biosystems founded?

T2 Biosystems was founded in 2014. It employs 51 to 100 people.

Where is T2 Biosystems based?

T2 Biosystems is headquartered in Lexington, United States, in the North America region.

How does T2 Biosystems make money?

One revenue line is on record: medical Diagnostics Equipment and Consumables.

Who are T2 Biosystems's main competitors?

Direct peers on record are bioMérieux, Cepheid (Danaher), Accelerate Diagnostics and GenMark Diagnostics. Broad incumbents are Becton, Dickinson and Company (BD), Roche Diagnostics, Hologic and QIAGEN. Emerging players are Tetracore and Qvella.

Does T2 Biosystems have an API?

No public API is recorded for T2 Biosystems.

What industry is T2 Biosystems in?

T2 Biosystems's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAH, Blood Bank, Transfusion Medicine & Immunohematology. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldT2 Biosystems (NASDAQ:TTOO) Share Price Crosses Above 50-Day Moving Average – Here’s What HappenedT2 Biosystems, Inc. (NASDAQ:TTOO) shares crossed above their 50-day moving average during trading on Monday, reaching a high of $0.0030 with a trading volume of 2,346 shares.Defense WorldT2 Biosystems (NASDAQ:TTOO) Stock Crosses Below 200-Day Moving Average – What’s Next?T2 Biosystems' stock (NASDAQ:TTOO) crossed below its 200-day moving average during Friday trading, reaching $0.0002 with a volume of 15,951 shares. The company has a market capitalization of approximately $4,208.60 and a PE ratio of 0.00. This technical indicator update follows the stock's decline from its 200-day moving average of $0.01.Defense WorldFinancial Analysis: Biostage (OTCMKTS:BSTG) and T2 Biosystems (NASDAQ:TTOO)This article presents a comparative financial analysis of two small-cap medical companies, T2 Biosystems and Biostage, evaluating them across 11 factors including earnings, valuation, profitability, institutional ownership, analyst recommendations, and risk metrics. The analysis finds that Biostage outperforms T2 Biosystems on 6 of the 11 comparison factors, with T2 Biosystems showing significantly higher losses at -$50.08 million compared to Biostage's -$6.07 million. Both companies are headquartered in Massachusetts and operate in the diagnostics and biotechnology sectors respectively.Defense WorldT2 Biosystems (NASDAQ:TTOO) Stock Passes Below 200-Day Moving Average – Time to Sell?T2 Biosystems stock crossed below its 200-day moving average during trading, with the stock last trading at $0.0002 and a volume of 2,700 shares. The company has a market cap of approximately $4,209, a P/E ratio of 0.00, and a beta of 0.82. T2 Biosystems is a commercial-stage diagnostics company focused on developing rapid diagnostic products using its proprietary T2 Magnetic Resonance technology for detecting pathogens and biomarkers in whole blood.PR NewswireT2 Biosystems, Inc. Announces Intent to Complete Winding Down of OperationsT2 Biosystems, Inc. announced it will immediately complete the winding down of operations and voluntarily liquidate the company. The decision follows failed attempts to sell the company or its assets since early 2025, after Nasdaq delisted the company's stock in February 2025 and all employees were terminated. The company stated it has extremely limited cash and significant liabilities, concluding that a wind down is the only viable path forward.GenomeWebT2 Biosystems to Wind Down OperationsT2 Biosystems announced it will immediately wind down operations and liquidate the company after Nasdaq suspended trading of its stock on Feb. 12, 2025, and subsequently terminated all employees. The firm stated it attempted to pursue a sale of the company or its assets, including intellectual property, since early last year but was unable to complete any transaction, citing extremely limited cash and significant liabilities as the reason a wind down is the only viable path forward. The company's T2Dx system received de novo FDA authorization in 2014 for pathogen identification and antimicrobial resistance testing directly from blood samples.MorningstarT2 Biosystems, Inc. Announces Intent to Complete Winding Down of OperationsT2 Biosystems, Inc. announced on February 3, 2026 that it will immediately complete winding down operations and voluntarily liquidate, concluding a process that began when it terminated all employees in February 2025. The company had attempted to find a buyer for its assets and intellectual property through an investment banking firm but was unable to complete any transaction that would satisfy its secured indebtedness. With extremely limited cash and significant liabilities, the company determined that a wind-down is the only viable path forward after Nasdaq delisted its common stock in February 2025.openPR.comUnited States Lyme Disease Diagnostics Market 2025: Industry Developments, Future Growth, Share & Industry Insights | T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Oxford Immunotec USA, Inc., ThermThe global Lyme disease diagnostics market is projected to grow from USD 1.6 billion in 2022 to USD 2.2 billion by 2030, a CAGR of 4.3% from 2024-2031. North America holds the largest share, with key players including T2 Biosystems, Bio-Rad, and Thermo Fisher. Recent developments include FDA clearance for new immunoblots and an AI-powered multiplex test.GlobeNewswireT2 Biosystems Inc. (TTOO): 2025 Product Pipeline and Strategy Analysis ReportResearchAndMarkets.com announced the addition of the 'T2 Biosystems Inc (TTOO) - Product Pipeline Analysis, 2025 Update' report to its market research offerings. The report provides an in-depth profile of T2 Biosystems, covering its diagnostic products including the T2Dx Instrument and various pathogen detection panels, along with competitive analysis of rival companies in the medical diagnostics space. The announcement targets investors and industry professionals seeking insights into T2 Biosystems' product development pipeline and market positioning.openPR.comEmerging Lyme Disease Diagnostics Market Opportunities and Competitive Landscape - T2 Biosystems, Inc., Bio-Rad Laboratories, Inc., Oxford Immunotec USA, Inc.,The global Lyme disease diagnostics market reached USD 1.6 billion in 2022 and is projected to reach USD 2.2 billion by 2030, a CAGR of 4.3%. Key players include T2 Biosystems, Bio-Rad, and Oxford Immunotec, while Moderna added two mRNA vaccine candidates to its pipeline in April 2023.